Tatyana Feldman, MD | Authors


Research Builds On Positive ECHELON-1 Study in Hodgkin Lymphoma

March 18, 2020

Tatyana Feldman, MD, director of T cell program at the John Theurer Cancer Center, Hackensack Meridian Health, discusses how research is now building upon the positive results from the phase III ECHELON-1 study, which was presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.

The Rationale for Exploring Brentuximab Vedotin Plus AVD in Hodgkin Lymphoma

December 19, 2017

Tatyana Feldman, MD, John Theurer Cancer Center, Hackensack University Medical Center, discusses the phase III Echelon-1 study, which found brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (AVD) demonstrated superior modified progression-free survival (PFS) versus ABVD in patients with previously untreated stage III or IV Hodgkin lymphoma.